On Monday, 23 December 2024, Eurofins Scientific SE (the “Company”) (EUFI.PA) announced its intention to launch a new buy-back programme of its own shares (ISIN FR0014000MR3) for a maximum amount representing up to 2% of its share capital. This fourth programme follows the first programme that took place between 3 October 2022 and 8 August 2023, the second programme that took place between 25 October 2023 and 30 August 2024, and the third programme that took place between 02 September 2024 and 20 December 2024. The new programme commenced on 23 December 2024 and will last until 22 December 2026 at the latest. The Company may at any time interrupt this programme in view of market conditions and/or the evolution of its investment strategy.

The shares to be purchased under this programme will be primarily used to hedge the Company’s Long-Term Incentive plans but may also be cancelled, used to partially finance acquisitions or for other purposes approved by the Board of Directors and within the authorisation of the AGM.

Over the course of the first tranches of this programme, which ran from 23 December 2024 to 25 February 2025, 2,130,000 shares were repurchased, representing 1.10% of the current share capital. The purpose allocation of the bought back shares is consistent with the objectives of the programme.

The Company has mandated an independent provider of financial services to execute the current tranche of this programme starting on 26 February 2025 and ending on 20 March 2025 with a maximum volume of 1,700,000 shares or 0.88% of its share capital.

In accordance with Market Abuse Regulation, transactions relating to share buy-back programmes are reported below.